penn surgery
penn surgery home penn surgery clinical penn surgery education penn surgery research penn surgery administration
 
Cardiovascular Research Laboratory
Harrison Department of Surgical Research
Y. Joseph Woo, M.D.
 

Clinical Research

 
Clinical Trials
  1. NIH U01 CT Surgery Network (Acker PI, Woo Co-Investigator): Penn is one of eight cardiac surgery centers selected by the NIH to conduct multicenter prospective randomized clinical trials in cardiac surgery. The first three studies will be: 1) Mitral Valve Repair vs. Mitral Valve Replacement for Severe Mitral Regurgitation in Ischemic Cardiomyopathy; 2) CABG with Mitral Valve Repair vs. CABG Alone for Patients with Coronary Artery Disease and Moderate Mitral Regurgitation; and 3) Atrial Fibrillation Ablation Surgery vs. Medical Therapy for Persistent Atrial Fibrillation.
  2. The RESTOR MV Clinical Trial (Woo PI): Penn is one of eight centers in the United States participating in this randomized trial comparing the safety and effectiveness of the Coapsys off-pump mitral valve repair device to standard ring annuloplasty for repair of moderate-to-severe mitral regurgitation.
  3. An Open Label Pilot Study to Obtain Tissue for Histological Analysis After Application of Anginera™ in Adults With A Left Ventricular Assist Device As A Bridge To Transplant (Margulies, Woo Co-PI’s): Anginera™ is a sterile, cryopreserved, human fibroblast-based tissue on a bioabsorbable ployglactin mesh scaffold (Vicryl™) which promotes angiogenesis. Anginera™ will be surgically implanted on the surface of the left ventricle of the heart at the time of LVAD placement. When the heart is later removed at the time of heart transplantation it will be evaluated histologically for the presence of new vasculature.
  4. A Phase I Open Label Pilot Study to Evaluate the Safety, Efficacy and Tolerability of Anginera for Adults With Left Ventricular Dysfunction AND Reversible Myocardial Ischemia undergoing CABG surgery (Woo PI): The primary objective is to evaluate the safety and tolerability of Anginera, a tissue engineered angiogenic cell sheet, in adults with Left Ventricular Dysfunction and Reversible Myocardial Ischemia undergoing a CABG procedure.
 
anginera patch
Placement of Anginera patch on ischemic area of myocardium which is not amenable to traditional revascularization.
 

footer

penn medicine